Introduction/Study Objectives: Different policies have been implemented to enhance uptake of biosimilars. As for demand-side policies, the literature has focused on interchangeability and substitutability recommendations, issued by national or regional policymakers. The evidence on actions taken by healthcare organisations (HCOs) on prescribing behaviour is limited. Furthermore, none investigated whether policies move from a policy framework aimed at appropriately reallocating resources gained through patent expiration. This paper aims at filling these gaps, investigating policies on biosimilars implemented at the local level in the Italian National Health Service.
Subscribe now to GaBI Journal to view full information of this article to be published in the next journal issue.